GSK Signs $30m Deal for Asthma, COPD Drugs

Apr 19, 2012, 03:00 AM by Michael Croft

San Francisco Business Times | GlaxoSmithKline has signed a second collaboration with Five Prime Therapeutics to develop drugs for asthma and COPD. Five Prime is eligible to receive payments up to $30 million over the next four years.

April 19, 2012 | GlaxoSmithKline has signed a second collaboration with Five Prime Therapeutics to develop drugs for asthma and COPD. Five Prime is eligible to receive payments up to $30 million over the next four years and up to $193.5 million in royalties. San Francisco Business Times